Tumores de la glándula suprarrenal

Fassnacht, 2016, Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors, Eur J Endocrinol, 175, 10.1530/EJE-16-0467 Cambos, 2020, Management of adrenal incidentalomas: working through uncertainty, Best Pract Res Clin Endocrinol Metab, 34, 101427, 10.1016/j.beem.2020.101427 Vezzosi, 2010, Pathogenesis of benign adrenocortical tumors, Best Pract Res Clin Endocrinol Metab, 24, 893, 10.1016/j.beem.2010.10.005 Beuschlein, 2014, Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome, N Engl J Med, 370, 1019, 10.1056/NEJMoa1310359 Espiard, 2015, The genetics of adrenocortical tumors, Endocrinol Metab Clin North Am, 44, 311, 10.1016/j.ecl.2015.02.004 Kamilaris, 2020, Adrenocortical tumorigenesis: lessons from genetics, Best Pract Res Clin Endocrinol Metab, 34, 101428, 10.1016/j.beem.2020.101428 Guignat, 2014, Cushing syndrome: when to suspect and how to confirm?, Presse Med, 43, 366, 10.1016/j.lpm.2014.02.005 Barat, 2022, Adrenal mass characterization in the era of quantitative imaging: state of the art, Cancers, 14, 569, 10.3390/cancers14030569 Lau, 2009, The Weiss system for evaluating adrenocortical neoplasms: 25 years later, Hum Pathol, 40, 757, 10.1016/j.humpath.2009.03.010 Choi, 2011, K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension, Science, 331, 768, 10.1126/science.1198785 Beuschlein, 2013, Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension, Nat Genet, 45, 440, 10.1038/ng.2550 Savard, 2013, Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study, Hypertension, 62, 331, 10.1161/HYPERTENSIONAHA.113.01060 Mulatero, 2020, Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the WorkingGroup on Endocrine Hypertension of The European Society of Hypertension, J Hypertens, 38, 1919, 10.1097/HJH.0000000000002510 Rossi, 2014, An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism, Hypertension, 63, 151, 10.1161/HYPERTENSIONAHA.113.02097 Lacroix, 2009, ACTH-independent macronodular adrenal hyperplasia, Best Pract Res Clin Endocrinol Metab, 23, 245, 10.1016/j.beem.2008.10.011 Libe, 2010, Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome, Eur J Endocrinol, 163, 129, 10.1530/EJE-10-0195 Vaczlavik, 2022, KDM1A inactivation causes hereditary food-dependent Cushing syndrome, Genet Med, 24, 374, 10.1016/j.gim.2021.09.018 Louiset, 2013, Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia, N Engl J Med, 369, 2115, 10.1056/NEJMoa1215245 Assie, 2013, ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome, N Engl J Med, 369, 2105, 10.1056/NEJMoa1304603 Espiard, 2015, ARMC5 mutations in a large cohort of primary macronodular adrenal hyperplasia: clinical and functional consequences, J Clin Endocrinol Metab, 100, E926, 10.1210/jc.2014-4204 Bertherat, 2006, Carney complex (CNC), Orphanet J Rare Dis, 1, 21, 10.1186/1750-1172-1-21 Stratakis, 1999, Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease, Ann Intern Med, 131, 585, 10.7326/0003-4819-131-8-199910190-00006 Else, 2014, Adrenocortical carcinoma, Endocr Rev, 35, 282, 10.1210/er.2013-1029 Fassnacht, 2018, European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors, Eur J Endocrinol, 179, G1, 10.1530/EJE-18-0608 ENDOCAN-COMETE. Thésaurus « Carcinome corticosurrénalien ». www.sfendocrino.org 2021. Assie, 2014, Integrated genomic characterization of adrenocortical carcinoma, Nat Genet, 46, 607, 10.1038/ng.2953 Arlt, 2011, Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors, J Clin Endocrinol Metab, 96, 3775, 10.1210/jc.2011-1565 Chortis, 2020, Urine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma, J Clin Endocrinol Metab, 105, e307, 10.1210/clinem/dgz141 Young, 2011, Conventional imaging in adrenocortical carcinoma: update and perspectives, Horm Cancer, 2, 341, 10.1007/s12672-011-0089-z Deandreis, 2011, FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma, Horm Cancer, 2, 354, 10.1007/s12672-011-0091-5 Weiss, 1984, Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors, Am J Surg Pathol, 8, 163, 10.1097/00000478-198403000-00001 Fassnacht, 2009, Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM Classification, Cancer, 115, 243, 10.1002/cncr.24030 Libé, 2015, Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study, Ann Oncol, 26, 2119, 10.1093/annonc/mdv329 Jouinot, 2018, Management of endocrine disease: adrenocortical carcinoma: differentiating the good from the poor prognosis tumors, Eur J Endocrinol, 178, R215, 10.1530/EJE-18-0027 Assié, 2019, Value of molecular classification for prognostic assessment of adrenocortical carcinoma, JAMA Oncol, 5, 1440, 10.1001/jamaoncol.2019.1558 Gaujoux, 2012, Recommendation for standardized surgical management of primary adrenocortical carcinoma, Surgery, 152, 123, 10.1016/j.surg.2011.09.030 De Francia, 2012, Mitotane treatment for adrenocortical carcinoma: an overview, Minerva Endocrinol, 37, 9 Fassnacht, 2012, Combination chemotherapy in advanced adrenocortical carcinoma, N Engl J Med, 366, 2189, 10.1056/NEJMoa1200966 Henning, 2017, Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors, J Clin Endocrinol Metab, 102, 4323, 10.1210/jc.2017-01624 Fassnacht, 2015, Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study, Lancet Oncol, 16, 426, 10.1016/S1470-2045(15)70081-1 Le Tourneau, 2018, Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial, J Immunother Cancer, 6, 111, 10.1186/s40425-018-0424-9 Lenders, 2020, Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension, J Hypertens, 38, 1443, 10.1097/HJH.0000000000002438 Buffet, 2020, An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma, Best Pract Res Clin Endocrinol Metab, 34, 101416, 10.1016/j.beem.2020.101416 ENDOCAN-COMETE. Thésaurus « Phéochromocytomes/paragangliomes malins ». www.sfendocrino.org 2021. Taïeb, 2019, European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma, Eur J Nucl Med Mol Imaging, 46, 2112, 10.1007/s00259-019-04398-1